COMPUTATIONAL DESIGN OF NORBORNANE-BASED HIV-1 PROTEASE INHIBITORS

被引:4
|
作者
Zhang, Dawei [1 ]
Yu, Liu Ze [1 ]
Huang, Philip Lin [2 ]
Lee-Huang, Sylvia [3 ]
Zhang, John Z. H. [4 ,5 ]
机构
[1] Nanyang Technol Univ, Sch Phys & Math Sci, Div Chem & Biol Chem, Singapore 637371, Singapore
[2] Amer Biosci, Boston, MA 02114 USA
[3] NYU, Dept Biochem, Langone Med Ctr, New York, NY 10016 USA
[4] E China Normal Univ, Dept Phys, State Key Lab Precis Spect, Shanghai 200062, Peoples R China
[5] NYU, Dept Chem, New York, NY 10003 USA
关键词
HIV-1; protease; norbornane-based inhibitor; linear interaction energy; FREE-ENERGY; LIGAND BINDING;
D O I
10.1142/S0219633610005773
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A series of norbornane-based HIV-1 protease (PR) inhibitors are designed theoretically to displace the tetrahedrally coordinated internal water molecule that bridges inhibitor to flaps via hydrogen bonds. These designed inhibitors use the norbornenone oxygen atom to mimic this structural water molecule and contain diols to interact with the carboxylate oxygens of catalytic aspartates. The binding free energies were estimated by modified linear interaction energy approach [Zoete H, Michielin O, Karplus M, J Comput Aided Mol Des 17: 861, 2003], in which the binding free energy is written as a linear combination of the electrostatic interaction energy between PR and the ligand, E-elec, the van der Waals interaction energy between PR and the ligand, E-vdW, and the difference of the solvation free energies of the complex, the receptor, and the isolated ligand, Delta G(solv). The equation obtained in previous work [Da W. Zhang, Philip Lin Huang, Sylvia Lee-Huang, John Z. H. Zhang, J Theor Comput Chem 7:485, 2008] is applied directly to calculate the binding free energy of designed norbornane-based HIV-1 PR inhibitors.
引用
收藏
页码:471 / 485
页数:15
相关论文
共 50 条
  • [1] Computational Notes on Fullerene Based System as HIV-1 Protease Inhibitors
    Ibrahim, Medhat
    Saleh, Noha A.
    Elshemey, Wael M.
    Elsayed, Anwar A.
    JOURNAL OF COMPUTATIONAL AND THEORETICAL NANOSCIENCE, 2010, 7 (01) : 224 - 227
  • [2] Drug design: New inhibitors for HIV-1 protease based on Nelfinavir as lead
    Perez, M. A. S.
    Fernandes, P. A.
    Ramos, M. J.
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2007, 26 (03) : 634 - 642
  • [3] Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors
    Monica, Gabriele La
    Lauria, Antonino
    Bono, Alessia
    Martorana, Annamaria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [4] Dimerization inhibitors of HIV-1 protease
    Boggetto, N
    Reboud-Ravaux, M
    BIOLOGICAL CHEMISTRY, 2002, 383 (09) : 1321 - 1324
  • [5] Computational design of novel cyclic urea as HIV-1 protease inhibitor
    Vijjulatha, Manga
    Kanth, S. Sree
    CENTRAL EUROPEAN JOURNAL OF CHEMISTRY, 2007, 5 (04): : 1064 - 1072
  • [6] Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance
    Stoffler, D
    Sanner, MF
    Morris, GM
    Olson, AJ
    Goodsell, DS
    PROTEINS-STRUCTURE FUNCTION AND GENETICS, 2002, 48 (01): : 63 - 74
  • [7] Lipopeptides as dimerization inhibitors of HIV-1 protease
    Schramm, HJ
    de Rosny, E
    Reboud-Ravaux, M
    Büttner, J
    Dick, A
    Schramm, W
    BIOLOGICAL CHEMISTRY, 1999, 380 (05) : 593 - 596
  • [8] Current development on HIV-1 protease inhibitors
    Aruksakunwong, Ornjira
    Promsri, Siriporn
    Wittayanarakul, Kitiyaporn
    Nimmanpipug, Piyarat
    Lee, Vannajan S.
    Wijitkosoom, Atchara
    Sompornpisut, Pornthep
    Hannongbua, Supot
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2007, 3 (03) : 201 - 213
  • [9] Chemometric classification of HIV-1 protease inhibitors
    Figueiredo, LJO
    Antunes, OAC
    INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY, 2000, 76 (06) : 744 - 755
  • [10] Fullerene-based inhibitors of HIV-1 protease
    Strom, T. Amanda
    Durdagi, Serdar
    Ersoz, Suha Salih
    Salmas, Ramin Ekhteiari
    Supuran, Claudiu T.
    Barron, Andrew R.
    JOURNAL OF PEPTIDE SCIENCE, 2015, 21 (12) : 862 - 870